Oregon Medical Research Center played a key role in a 2023 FDA approval, showcasing its dedication to clinical research and bringing innovative treatment options to patients.
Ritlecitinib (Pfizer) for Alopecia Areata
In June of 2023, the FDA approved Pfizer’s LITFULO (Ritlecitinib) for the treatment of severe alopecia areata. This is one of only two drugs currently on the market, and the only available for adolescents 12 and older. With the participation of our wonderful patients, Oregon Medical Research Center contributed to the pivotal ALLEGRO study, supporting the approval of Ritlecitnib. Nicole Friedland, President and Chief Executive Officer of the National Alopecia Areata Foundation (NAAF) shared, “We believe the approval of LITFULO is a significant advancement for the treatment of alopecia areata, particularly for teens. It’s exciting to see more FDA-approved treatments becoming available for this community.” 1
1. FDA approves Pfizer’s LITFULOTM (Ritlecitinib) for adults and adolescents with severe alopecia areata | Pfizer.